Commentary: COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next

Metabolism. 2020 Jun:107:154245. doi: 10.1016/j.metabol.2020.154245. Epub 2020 Apr 19.

Authors

Angeliki M Angelidi¹, Matthew J Belanger¹, Christos S Mantzoros²

Affiliations

¹ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
² Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Section of Endocrinology, VA Boston Healthcare System, Harvard Medical School, Boston, MA 02115, USA. Electronic address: cmantzor@bidmc.harvard.edu.

No abstract available

Keywords: COVID-19; Diabetes; Evidence-based practice; Renin-angiotensin system; Risk; SARS-CoV-2; Therapy.

MeSH terms

Angiotensin-Converting Enzyme 2
Betacoronavirus
COVID-19
Comorbidity
Coronavirus Infections / complications*
Coronavirus Infections / immunology
Diabetes Mellitus / therapy*
Diabetes Mellitus / virology
Humans
Pandemics
Peptidyl-Dipeptidase A
Pneumonia, Viral / complications*
Pneumonia, Viral / immunology
Risk Factors
SARS-CoV-2

Substances

Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2